Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer

Oncologist

Volumn 17, Issue 5, 2012, Pages 682-693

  Stinchcombe, Thomas E ^a   Bogart, Jeffrey A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Adaptive radiotherapy; Bevacizumab; Cetuximab; Epidermal growth factor receptor; High dose thoracic radiation therapy; Hypofractionation; Radiation therapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EMEPEPIMUT S; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE;

AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INDUCTION CHEMOTHERAPY; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; TRACHEOESOPHAGEAL FISTULA; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 84861601340     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0020     Document Type: Article

References (87)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
4. Auperin A, le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-2190.
5. Furuse K; West Japan Lung Cancer Group. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-2699.
6. Curran WJ Jr, Paulus R, Langer CJ et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-1460.
7. Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol 2005;23:5910-5917.
8. Segawa Y, Kiura K, Takigawa N et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010;28:3299-3306.
9. Yamamoto N, Nakagawa K, Nishimura Y et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJ-TOG0105. J Clin Oncol 2010;28:3739-3745.
10. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
11. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
12. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
13. Govindan R, Bogart J, Stinchcombe T et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407. J Clin Oncol 2011;29:3120-3125.
14. Gadgeel SM, Ruckdeschel JC, Patel BB et al. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol 2011;6:927-933.
15. Brade AM, Bezjak A, MacRae RM et al. A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:7087.
16. Xu Y, Ma S, Ji Y et al. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. Lung Cancer 2011;72:327-332.
17. Choy H, Schwartzberg LS, Dakhil SR, et al. Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorableprognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update [abstract 7082]. J Clin Oncol 2010;28:15s.
18. Vokes EE, Senan S, Treat JA et al. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10:193-198.
19. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
20. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
21. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-1531.
22. Blumenschein GR Jr, Paulus R, Curran WJ et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-2318.
23. Available at http://www.clinicaltrials.gov. Accessed December 29, 2011.
24. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-1818.
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
26. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
27. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128.
28. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
29. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
30. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
31. Rigas JR, Carey MA, Rubin MS et al. Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation (D0410, NCT001538803). J Thorac Oncol 2009;4:s371.
32. Raben D, Helfrich B, Chan D et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002;29:37-46.
33. Chinnaiyan P, Huang S, Vallabhaneni G et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-3335.
34. Stinchcombe TE, Morris DE, Lee CB et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008;3:250-257.
35. Choong NW, Mauer AM, Haraf DJ et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008;3:1003-1011.
36. Ball D, Burmeister B, Mitchell P et al. Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer (CRITICAL): P2-162. J Thorac Oncol 2007;2:S633-S634.
37. Center B, Petty WJ, Ayala D et al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 2010;5:69-74.
38. Rothschild S, Bucher SE, Bernier J et al. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: A phase I trial. Int J Radiat Oncol Biol Phys 2011;80:126-132.
39. Ready N, Janne PA, Bogart J et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010;5:1382-1390.
40. Komaki R, Blumenschein GR, Wistuba II et al. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. J Clin Oncol 2011;29:7020.
41. Yoneda KY, Hardin KA, Gandara DR et al. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in nonsmall-cell lung carcinoma. Clin Lung Cancer 2006;8: S31-S35.
42. Wan J, Cohen V, Agulnik J et al. Unexpected high lung toxicity from radiation pneumonitis in a phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2009;75:S110.
43. Okamoto I, Takahashi T, Okamoto H et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 2011;72:199-204.
44. Ohe Y, Nishiwaki Y, Yokoyama A et al. Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. J Clin Oncol 2010;28:7084.
45. Davies AM, Ho C, Lara PN Jr et al. Pharmacodynamic separation of epidermal growth factor receptor ty- rosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-388.
46. Janne PA, Wang XF, Socinski MA et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010;28:7503.
47. Sandler A, Gray R, Perry MC et al. Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
48. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27: 1227-1234.
49. Reck M, von Pawel J, Zatloukal P etal. Overall sur-vival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
50. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
51. Gorski DH, Mauceri HJ, Salloum RM et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-5689.
52. Mauceri HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-291.
53. Spigel DR, Hainsworth JD, Yardley DA et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-48.
54. Stinchcombe T, Socinski MA, Moore DT et al. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract 7082]. J Clin Oncol 2010;28:15s.
55. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681.
56. Available at http://www.clinicaltrials.gov. Accessed February 19, 2012.
57. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 2009;14:253-263.
58. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
59. Azzoli CG, Baker S, Jr. Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
60. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
61. Bradley JD, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy cetuximab for stage IIIa/IIIb non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617. Presented at the 53rd ASTRO Annual Meeting, Miami Beach, Florida, October 3, 2011.
62. Socinski MA, Blackstock AW, Bogart JA et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-2463.
63. Schild SE, McGinnis WL, Graham D et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65: 1106-1111.
64. Bradley JD, Bae K, Graham MV et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol 2010;28:2475-2480.
65. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
66. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000;46:516-517.
67. Cox JD, Pajak TF, Asbell S et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993;27:493-498.
68. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174.
69. Saunders M, Dische S, Barrett A et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-165.
70. Mehra MP, Tannehill SP, Adak S et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 1998;16:3518-3523.
71. Belani CP, Wang W, Johnson DH et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005;23:3760-3767.
72. Graham MV, Pajak TE, Herskovic AM et al. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 8312): Long-term results. Int J Radiat Oncol Biol Phys 1995;31:819-825.
73. Pemberton LS, Din OS, Fisher PM et al. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: A single-centre retrospective study of outcome. Clin Oncol (R Coll Radiol) 2009; 21:161-167.
74. Uitterhoeve AL, Belderbos JS, Koolen MG et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer 2000;36:592-600.
75. Belderbos J, Uitterhoeve L, van Zandwijk N et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-121.
76. Maguire J.: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. J Clin Oncol 2011;29:7039.
77. Maguire JLM, Walshaw M. Enhanced local control and survival with concurrent chemoradiation using accelerated hypofractionated radiotherapy. Presented at the Multidisciplinary Thoracic Oncology Meeting, Chicago, Illinois, December 9-11,2010.
78. Cho KH, Ahn SJ, Pyo HR et al. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: Results of Korean Radi- ation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys 2009;74:1397-1404.
79. Bogart JA, Hodgson L, Seagren SL et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol 2010;28:202-206.
80. Mac Manus MP, Hicks RJ, Ball DL et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895.
81. Bujold A, Craig T, Jaffray D et al. Image-guided radiotherapy: Has it influenced patient outcomes? Semin Radiat Oncol 2012;22:50-61.
82. Kong F-MS, Xiao Y, Machtay M et al. Using during-RT PET to individualize adaptive RT for patients with stage III NSCLC: A RTOG planning study [abstract 2818]. Presented at the American Society for Radiation Oncology 2011 Annual Meeting, Miami Beach, Florida, October 2-6, 2011.
83. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
84. Timmerman R, McGarry R, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin On-col 2006;24:4833-4839.
85. Feddock J, McGarry R. Safety and toxicity of linac-based stereotactic body radiotherapy (SBRT) boost to residual disease in locally advanced non-small cell lung cancer: Preliminary results of a single institution feasibility study. Int J Radiat Oncol Biol Phys 2010; 78:s108.
86. Bush DA. Proton radiation therapy for lung cancer: Is there enough evidence? Oncology (Williston Park) 2010;24:1052-1057.
87. Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: Clinical outcomes and technical issues. A systematic review. Radiother Oncol 2008; 86:154-164.